Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 4 1Phase 3 1

Status

Completed 5Unknown 4Terminated 2Recruiting 1

Sponsor Class

OTHER 5

Study Type

Interventional 5

Sponsor

Cancer Type

Plasma cell 4Other hematologic neoplasm 1

Conditions

Multiple Myeloma 81Neoplasms, Plasma Cell 27Neoplasms 13Brain Neoplasms 11Prostatic Neoplasms 10Central Nervous System Neoplasms 10Melanoma 9Leukemia 9Glioblastoma 8Gliosarcoma 7Glioma 7Leukemia, Lymphocytic, Chronic, B-Cell 6Carcinoma, Hepatocellular 6Recurrence 5Myeloproliferative Disorders 5Myelodysplastic Syndromes 5Lymphoma, Mantle-Cell 5Lung Neoplasms 5Waldenstrom Macroglobulinemia 4Sarcoma 4Myelodysplastic-Myeloproliferative Diseases 4Lymphoma, B-Cell, Marginal Zone 4Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 4Immunoglobulin Light-chain Amyloidosis 4Carcinoma, Renal Cell 4Uveal Melanoma 3Oligodendroglioma 3Neuroblastoma 3Lymphoma, Non-Hodgkin 3Lymphoma, Follicular 3

Interventions

Cyclophosphamide 67Dexamethasone 52Peripheral Blood Stem Cell Transplantation 37Lenalidomide 37Rituximab 35fludarabine phosphate 34Bortezomib 30Filgrastim 27Etoposide 27Cytarabine 25Carboplatin 25Busulfan 23Radiotherapy 22Melphalan 22Gemcitabine 22Cyclosporine 21pomalidomide 20fludarabine 20Whole-Body Irradiation 20Mycophenolic Acid 20Paclitaxel 19Methotrexate 18venetoclax 17Cisplatin 17pembrolizumab 16Calcium Dobesilate 16Bevacizumab 16Tacrolimus 14Antilymphocyte Serum 14Nivolumab 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Completed × Recurrence × Thalidomide × Clear all
NCT01526694 2018-07-03

Phase II Trial Designed to Determine Efficacy and Safety of Bendamustine+Dexamethasone+Thalidomide in R/R MM

Azienda Ospedaliera di Bolzano

Phase 2 Completed
30 enrolled
Plasma cell

Multiple Myeloma, Recurrence

NCT00652041 2011-09-19

TaCyDexVMP7

PETHEMA Foundation

Phase 4 Completed
40 enrolled
Plasma cell

Multiple Myeloma, Recurrence

NCT00602511 2011-02-09

Thalidomide Versus Bortezomib in Melphalan Refractory Myeloma

Nordic Myeloma Study Group

Phase 3 Completed
300 enrolled
Plasma cell

Multiple Myeloma, Recurrence

NCT00083681 2010-07-02

DCEP in Combination With Thalidomide as Salvage Therapy for Post Transplantation Relapse

University of Arkansas

Phase 2 Completed
180 enrolled
Plasma cell

Multiple Myeloma, Recurrence

NCT00083694 2010-07-02

Thalidomide Anti-Angiogenesis Therapy of Relapsed or Refractory Leukemia

University of Arkansas

Phase 2 Completed
25 enrolled
Other hematologic neoplasm

Leukemia, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡